BI 2536 Chemical Properties

Density 

1.28

storage temp. 

Keep in dark place,Sealed in dry,Store in freezer, under -20°C

solubility 

Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)

form 

Yellow powder.

pka

14.09±0.20(Predicted)

color 

Off-white

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

BI 2536 Usage And Synthesis

Description

BI 2536 (755038-02-9) was originally reported as a potent (IC50’s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM)1?and selective2?Polo-like kinase inhibitor?that caused mitotic arrest and apoptosis induction in various human cancer cell lines.1?It was later found to be a potent inhibitor (IC50?= 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells.3?BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.4

Uses

BI 2536 is a PLK1 inhibitor, inducing apoptosis together with micro-tubule-destabilizing drugs in preclinical rhabdomyosarcoma models. Anti-cancer and potent PLK1 inhibitor.

target

Plk1

References

1) Steegmaier?et al.?(2007),?BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo; Curr. Biol.,?17?316 2) Davis?et al.?(2011),?Comprehensive analysis of kinase inhibitor selectivity; Nat. Biotechnol.,?29?1046 3) Ciceri?et al.?(2014),?Dual kinase-bromodomain inhibitors for rationally designed polypharmacology; Nat. Chem. Biol.,?10?305 4) Xiao?et al.?(2016),?Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival; Mol. Cell,?64?493

BI 2536(755038-02-9)Related Product Information

• D-ERYTHRO-SPHINGOSINE
• Bortezomib
• Alisertib (MLN8237)
• PD 0332991 HCl
• Volasertib (BI 6727)
• Afatinib
• Olaparib
• Selumetinib
• BML-275
• PLX-4720
• CX-4945
• Fluoxetine hydrochloride
• Alpelisib (BYL719)
• Tubastatin A hydrochloride
• N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride
• Neratinib
• Glucagon Receptor Antagonist I
• BI 2536